To contribute to the development of the respiratory discipline and provide new treatment options for the management of asthma and other chronic inflammatory airway diseases in China, Beijing Grand Jiuhe Pharmaceutical Co., Ltd., a member company of the respiratory and critical care segment of Grand Pharma, presented its global innovative product at the 2024 Annual Congress of the Chinese Association of Chest Physicians, CMDA, which took place from June 13th to 16th in Suzhou, China.

Under the theme of “Deep understanding of the attending physician responsibility system and its active implementation”, the conference explored the future development direction of respiratory medicine.
During the conference, two symposia, “Management of Airway Mucus Hypersecretion in Chronic Inflammatory Diseases” and “New Options for Optimizing Asthma Management from GINA2024”, were specially set up.
These two symposia were co-chaired by Prof. Cao Bin, Chairman-designate of the Respiratory Disease Branch of the Chinese Medical Association, and Prof. Xie Lixin, National Member of the Respiratory Disease Branch of the Chinese Medical Association and Head of the Respiratory Therapy Group.
The conference invited many experts and scholars, such as Prof. Zhang Min, Vice Chairman of the Asthma Group of the Respiratory Division of the Chinese Medical Association, and Prof. Yao Xin, member of the Asthma Group of the Respiratory Division of the Chinese Medical Association, and member of the Elective Committee of the Allergy Division of the Jiangsu Provincial Medical Association.
The conference centered on the GINA2024 update and the issue of airway mucus hypersecretion in chronic airway diseases, which brought a feast of academic discussions with high specifications and professionalism to the participants.